Discover Immuneering’s latest breakthrough: atebimetinib delivers unprecedented survival rates in first-line pancreatic cancer.
Immuneering Corporation - Special CallCompany ParticipantsBenjamin Zeskind - Co-Founder, President, CEO & DirectorConference Call ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback